Original citation:
Waris, Sahar, Winklhofer-Roob, Brigitte M., Roob, Johannes M., Fuchs, Sebastian, Sourij, Harald, Rabbani, Naila and Thornalley, Paul J. (2015) R : Increased DNA dicarbonyl glycation and oxidation markers in patients with type 2 diabetes and link to diabetic nephropathy. Journal of Diabetes Research, Volume number 2015 . pp. 1-10. Article Number 915486.

Permanent WRAP url:
http://wrap.warwick.ac.uk/67576

Copyright and reuse:
The Warwick Research Archive Portal (WRAP) makes this work of researchers of the University of Warwick available open access under the following conditions. This article is made available under the Creative Commons Attribution 3.0 Unported (CC BY 3.0) license and may be reused according to the conditions of the license. For more details see: http://creativecommons.org/licenses/by/3.0/

A note on versions:
The version presented in WRAP is the published version, or, version of record, and may be cited as it appears here.

For more information, please contact the WRAP Team at: publications@warwick.ac.uk

http://wrap.warwick.ac.uk
Research Article

Increased DNA Dicarbonyl Glycation and Oxidation Markers in Patients with Type 2 Diabetes and Link to Diabetic Nephropathy

Sahar Waris,1 Brigitte M. Winkhofer-Roob,2 Johannes M. Roob,3 Sebastian Fuchs,2 Harald Sourij,4 Naila Rabbani,1,5 and Paul J. Thornalley1,5

1 Warwick Medical School, Clinical Sciences Research Laboratories, University of Warwick, University Hospital, Coventry CV2 2DX, UK
2 Human Nutrition & Metabolism Research and Training Center Graz, Institute of Molecular Biosciences, Karl Franzens University, 8010 Graz, Austria
3 Clinical Division of Nephrology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria
4 Clinical Division of Endocrinology and Nuclear Medicine, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria
5 Warwick Systems Biology Centre, Senate House, University of Warwick, Coventry CV4 7AL, UK

Correspondence should be addressed to Naila Rabbani; n.rabbani@warwick.ac.uk

Received 1 January 2015; Revised 14 March 2015; Accepted 23 March 2015

Academic Editor: Patrizio Tatti

Copyright © 2015 Sahar Waris et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Aim. The aim of this study was to assess the changes of markers of DNA damage by glycation and oxidation in patients with type 2 diabetes and the association with diabetic nephropathy. Methodology. DNA oxidation and glycation adducts were analysed in plasma and urine by stable isotopic dilution analysis liquid chromatography-tandem mass spectrometry. DNA markers analysed were as follows: the oxidation adduct 7,8-dihydro-8-oxo-2′-deoxyguanosine (8-OxodG) and glycation adducts of glyoxal and methylglyoxal—imidazopurinones GdG, MGdG, and N2-1,R,S-carboxyethyl)deoxyguanosine (CEdG). Results. Plasma 8-OxodG and GdG were increased 2-fold and 6-fold, respectively, in patients with type 2 diabetes, with respect to healthy volunteers. Median urinary excretion rates of 8-OxodG, GdG, MGdG, and CEdG were increased 28-fold, 10-fold, 2-fold, and 2-fold, respectively, in patients with type 2 diabetes with respect to healthy controls. In patients with type 2 diabetes, nephropathy was associated with increased plasma 8-OxodG and increased urinary GdG and CEdG. In a multiple logistic regression model for diabetic nephropathy, diabetic nephropathy was linked to systolic blood pressure and urinary CEdG. Conclusion. DNA oxidative and glycation damage-derived nucleoside adducts are increased in plasma and urine of patients with type 2 diabetes and further increased in patients with diabetic nephropathy.

1. Introduction

Reactive oxygen species (ROS) and dicarbonyl metabolites, glyoxal and methylglyoxal, are some of the most reactive metabolites present in human metabolism. They are increased in diabetes and diabetic nephropathy [1–3]. ROS react with deoxyguanosine residues of DNA to form 8-dihydro-8-oxo-2′-deoxyguanosine (8-OxodG). The DNA content of 8-OxodG residues was increased in lymphocyte DNA in clinical diabetes [4]. Reactive dicarbonyl intermediates of endogenous glycation, glyoxal and methylglyoxal, also react with deoxyguanosine residues of DNA to form mainly imidazopurinone adducts. Glyoxal forms 3-(2′-deoxyribosyl)-6, 7-dihydro-6, 7-dihydroxyimidazo-[2,3-b] purine-9(8)one (GdG) and methylglyoxal forms two imidazopurinone structural isomers, 3-(2′-deoxyribosyl)-6,7-dihydro6, 7-dihydroxy-6/7-methylimidazo-[2,3-b]purine-9(8)one (MGdG). DNA glycation by methylglyoxal also forms two stereoisomers, N2-modified derivatives, N2-(1,R,S-carboxyethyl)-deoxyguanosine (CEdG) [5]. Figure 1(a). GdG, MGdG, and CEdG are nucleotide advanced glycation endproducts (AGEs). Methylglyoxal-derived MGdG was a quantitatively major adduct of endogenous damage in healthy volunteers [5]. Damage to DNA by endogenous glyoxal and
FIGURE 1: Continued.
FIGURE 1: Continued.
methylglyoxal is suppressed by glyoxalase 1 (Glo1) of the cytoplasmic glyoxalase system [6]. The expression and activity of Glo1 in the kidney were decreased in experimental models of diabetic nephropathy—streptozotocin-induced diabetes in mice and rats and the db/db diabetic mouse [7–9]. This is associated with increased dicarbonyl glycation of proteins linked to the development of diabetic nephropathy [10]. Increased urinary 8-OxodG excretion has been found in patients with diabetes type 2 diabetes (T2DM), with further increases associated with the presence of microvascular complications, and was a predictor of diabetic nephropathy [11, 12].

Nucleotide AGEs are associated with DNA single-strand breaks and increased mutation frequencies [13]. Oxidised and glycated nucleosides are removed from DNA by nucleotide excision repair of DNA damaged by oxidation and glycation. Recent functional genomic studies of Glo1 have linked dicarbonyl glycation to the development of diabetic nephropathy [14, 15]. The plasma concentration and urinary fluxes of glyoxal and methylglyoxal-derived nucleoside AGEs in diabetes and diabetic nephropathy are unknown.

Reliable quantification of oxidised and glycated nucleosides has proven difficult because of inadequate sensitivity and specificity of detection responses and poor adduct stability and recovery during preanalytic processing. Initial studies involved 32P-labelling studies of DNA digests [16] and immunoassay [17]. Stable isotopic dilution analysis liquid chromatography with tandem mass spectrometric detection (LC-MS/MS) has been used for assay of 8-OxodG [18]. For estimation of both DNA glycation and oxidation adducts, the high specificity and sensitivity of LC-MS/MS makes this the preferred method for DNA damage marker analysis.

We developed a stable isotopic dilution analysis LC-MS/MS method to concurrently quantify GdG, MGdG, CEdG, and 8-OxodG in plasma and urinary ultrafiltrate [5]. 8-OxodG has been studied extensively in plasma and urine as a biomarker of oxidative damage [18] whereas the diagnostic utility of DNA glycation adducts is unknown.

Herein we analysed DNA oxidation and glycation markers in plasma and urine of patients with T2DM with and without diabetic nephropathy. Healthy volunteers served as controls. The outcome revealed marked increases in DNA damage in T2DM and further increase of selected markers in diabetic nephropathy. Increased urinary excretion of glycation adducts GdG and CEdG was indicative of diabetic nephropathy.

2. Methods

2.1. Participants. Patients with type 2 diabetes and overt nephropathy (T2DM + DN) and patients with T2DM and without overt nephropathy (T2DM − DN) were recruited in the EU-funded PREDICTIONS project [19]. Healthy volunteers were recruited in the EU-funded VITAGE project [20]. Both studies were conducted at the Human Nutrition and Metabolism Research and Training Center, Karl Franzens University of Graz, Austria, and the Clinical Division of Nephrology and the Clinical Division of Endocrinology and Nuclear Medicine, Department of Internal Medicine, Medical University of Graz, Austria. The study protocols were approved by the Ethics Committee of the Medical University of Graz, Austria, and written informed consent was obtained from all study subjects. Diagnosis of diabetes was established in accordance with the WHO criteria:

![Figure 1](image1.png)
fasting plasma glucose ≥7.0 mmol/L, a two-hour value in an oral glucose tolerance test 11.1 mmol/L, or random plasma glucose 11.1 mmol/L in the presence of symptoms, aged 35–75 with a documented duration of diabetes of ≥5 years being eligible. T2DM was diagnosed by lack of criteria for type 1 diabetes. Inclusion criteria were cases who had albuminuria >300 mg/d and known overt diabetic retinopathy. Retinopathy was requested to be present to ensure that albuminuria is the consequence of diabetic nephropathy rather than a nondiabetic glomerulopathy. A renal biopsy would be the gold standard to discriminate between diabetic nephropathy and a nondiabetic glomerulopathy, but a renal biopsy is rarely taken in patients with T2DM. Several studies have indicated that presence of retinopathy is a good alternative inclusion criterion to discriminate between diabetic nephropathy and nondiabetic glomerulopathy in patients with T2DM with albuminuria [21–23]. Exclusion criteria were chronic renal failure, known causes of renal failure other than diabetes, and non-Caucasian ethnic origin. Cases and controls were matched for gender and diabetes duration. Exclusion criteria for T2DM-DN were microalbuminuria, non-Caucasian ethnic origin, and, in case of use of RAAS-blocking medication, unknown albuminuria status prior to the start of treatment. Estimated GFR (eGFR) was determined by the Chronic Kidney Disease Epidemiology Collaboration equations: for females (for whom \([\text{Creatinine}]_{\text{plasma}}\) was >62 µM), eGFR = 144 x \(\left[\frac{\text{Creatinine}}{\mu M}\right]_{\text{plasma}}(62)^{-1.209}\) x (0.993)\(^{\text{Age}}\); and, for males, when \([\text{Creatinine}]_{\text{plasma}}\) ≤ 80 µM, eGFR = 141 x \(\left[\frac{\text{Creatinine}}{\mu M}\right]_{\text{plasma}}(80)^{-0.411}\) x (0.993)\(^{\text{Age}}\), and when \([\text{Creatinine}]_{\text{plasma}}\) > 80 µM, eGFR = 141 x \(\left[\frac{\text{Creatinine}}{\mu M}\right]_{\text{plasma}}(80)^{-1.209}\) x (0.993)\(^{\text{Age}}\) [24]. Glycated haemoglobin (A1C) was determined by a validated ion exchange high pressure chromatography method (Menarini ARKRAY ADAMS A1C HA-8180 analyser, Menarini Diagnostics, Florence, Italy) [25]. Subject characteristics are given in Table 1.

### 2.2. Methods

Venous blood samples were collected from all study subjects after overnight fast and plasma samples were prepared immediately and stored at −80°C until analysis; 24 h urines collections were made and aliquots prepared and stored at −80°C until analysis. Ultrafiltrates were prepared by microspin ultrafiltration (10 kDa cut-off) of plasma and urine (100 µL), collecting ca. 50 µL ultrafiltrate. Sample processing and storage validation were published previously [5].

Nucleotide markers of glycation and oxidation were determined by stable isotopic dilution analysis LC-MS/MS. GdG, MgGdG, CEdG, and 8-OxodG and related stable isotopic \(^{15}\)C\(_{10}\), \(^{15}\)N\(_5\) substituted standards were prepared as described [5]. For LC-MS/MS, plasma and urine ultrafiltrates (40 µL) were spiked with 10 µL isotopic standard mixture containing 0.1 nmol \(^{15}\)C\(_{10}\), \(^{15}\)N\(_5\) dG, 1 pmol \(^{15}\)C\(_{10}\), \(^{15}\)N\(_5\) 8-OxodG, 1pmol \(^{15}\)C\(_{10}\), \(^{15}\)N\(_5\) MgGdG and CEdG, and 1pmol \(^{15}\)C\(_{10}\), \(^{15}\)N\(_5\) GdG. LC-MS/MS was performed using an Acquity UPLC-Quattro Premier tandem mass spectrometer with a BEH C18 1.7 µm particle size, 2.1 x 100 mm column. The mobile phase (0.25 mL/min) was 0.1% formic acid with a linear gradient of 0–10% acetonitrile from 2 to 10 min and isocratic 10% acetonitrile from 10 to 15 min. After analysis, the column was washed with 50% acetonitrile, 0.1% formic acid for 10 min and thereafter reequilibrated with initial mobile phase for 10 min. The column temperature was varied from 10°C. For GdG, MgGdG, CEdG, and 8-OxodG, limits of detection were 0.8, 2.5, 2.2, and 0.7 fmol; analytical recoveries were 104, 97, 98%, and 99%, respectively, and coefficients of variation 2–7% [5].

| Subject group | Control | T2DM-DN | T2DM+DN |
|---------------|---------|---------|---------|
| n | 28 | 28 | 28 |
| Age (years) | 61 ± 8 | 63 ± 6 | 60 ± 10 |
| Gender (M/F) | 28/0 | 20/8 | 20/8 |
| BMI (kg/m²) | 26.1 ± 1.8 | 28.5 ± 5.0* | 33.2 ± 5.0***,***000 |
| Fasting plasma glucose (mM) | 5.6 ± 0.5 | 9.4 ± 3.0*** | 9.3 ± 3.8*** |
| AIC (%) | ND | 7.6 ± 1.2 | 7.5 ± 1.5 |
| (mmol/mol) | | 60 ± 13 | 58 ± 17 |
| Systolic BP (mmHg) | 135 ± 13 | 136 ± 13 | 153 ± 22*** |
| Diastolic BP (mmHg) | 84 ± 6 | 81 ± 10 | 84 ± 10 |
| Total cholesterol (mM) | 5.52 ± 0.94 | 5.04 ± 1.13 | 5.17 ± 1.14 |
| LDL cholesterol (mM) | 3.31 ± 0.69 | 2.92 ± 0.96 | 2.58 ± 0.92* |
| HDL cholesterol (mM) | 1.49 ± 0.32 | 1.46 ± 0.38 | 1.40 ± 0.29 |
| Urinary albumin (mg/24 h) | ND | 13 ± 10 | 2437 (371−9000)*** |
| eGFR (ml/min) | 69 ± 13 | 73 ± 13 | 31.7 (20.0−45.3)***,***000 |

ND = not determined. Data are mean ± SD or median (minimum–maximum). Significance: * and ***. P < 0.05 and P < 0.001 with respect to healthy volunteers, and ***, P < 0.001 with respect to patients with type 2 diabetes without nephropathy.
2.3. Statistical Analysis. Data are median (minimum–maximum) or median (lower–upper quartile) values. Significance of differences between means was assessed by Mann-Whitney U test. Bivariate regression was nonparametric (Spearman) and logistic regression was performed of DN on continuous variables, excluding the recruitment qualifier of urinary albumin, solving for regression coefficient $B_0$. Statistical analysis was performed by the SPSS software, v21.

3. Results

3.1. DNA Glycation Adducts in Plasma and Urine. Biomarkers of nucleotide glycation and oxidation are conveniently determined by assay of glycated and oxidised nucleosides in plasma and urine ultrafiltrates. This was performed with samples from healthy controls and patients with T2DM with and without diabetic nephropathy. Median plasma concentrations of GdG, MGDG, CEdG, and 8-OxodG in healthy subjects were 0.07, 0.34, 0.14, and 0.08 nM, respectively. Plasma GdG was increased 6-fold and plasma 8-OxodG increased 2-fold in patients with T2DM. Median urinary excretion rates of GdG, MGDG, CEdG, and 8-OxodG in healthy subjects were 0.23, 2.63, 0.90, and 0.90 nmol/24 h, respectively. In patients with T2DM, urinary GdG, MGDG, CEdG, and 8-OxodG were increased 10-fold, 2-fold, 2-fold, and 28-fold, respectively, Figures 1(b)–1(i).

We also assessed the effect of diabetic nephropathy (DN) in patients with T2DM on plasma and urinary nucleotide glycation and oxidation damage markers. In plasma, median 8-OxodG concentration was increased 30% in DN and in urine GdG was increased 24% and CEdG increased 60% in diabetic nephropathy, Figures 1(j)–1(l).

3.2. Correlation Analysis. Bivariate correlation analysis of clinical chemistry variables of renal function with nucleoside glycation and oxidation analytes in patients with T2DM is given in Table 2. As expected, there were a strong negative correlation of plasma creatinine with eGFR ($r = -0.95$, $P < 0.001$), a strong positive correlation of plasma creatinine with urinary albumin excretion UAE ($r = 0.61$, $P < 0.001$), and a strong negative correction of eGFR with UAE ($r = -0.55$, $P < 0.001$). There were also positive correlations of urinary excretions of GdG and CEdG with UAE ($r = 0.38$ and 0.42, resp., $P < 0.01$) and a positive correlation of plasma 8-OxodG with plasma creatinine ($r = 0.38$, $P < 0.01$). For correlation between nucleotide glycation and oxidation analytes, in plasma there were a strong positive correlation of MGDG with CEdG ($r = 0.46$, $P < 0.001$) and also positive correlation of MGDG with 8-OxodG ($r = 0.45$, $P < 0.01$) and GdG with CEdG ($r = 0.47$, $P < 0.01$). For urinary excretion, there was a positive correlation of MGDG excretion with 8-OxodG excretion ($r = 0.37$, $P < 0.01$). There was also a positive correlation of plasma MGDG with urinary MGDG ($r = 0.41$, $P < 0.01$) but there were no similar correlations of plasma and urinary levels of other nucleotide glycation and oxidation analytes. There was no correlation of clinical chemistry variables of glycemic control (fasting plasma glucose, A1C), total cholesterol, LDL cholesterol, HDL, or systolic and diastolic blood pressure with nucleotide glycation and oxidation markers.

In a multiple logistic regression analysis of diabetic nephropathy on clinical and clinical chemistry variables, the following variables were included: clinical variables previously associated with diabetic nephropathy (age, gender, A1C, systolic and diastolic blood pressure, and total cholesterol) [21, 26], related markers of metabolic control (fasting plasma glucose, LDL, and HDL), other factors linked to increased glyoxal and methylglyoxal (duration of diabetes, BMI) [1, 22], and markers of DNA glycation and oxidation measured noninvasively (urinary excretions of GdG, MGDG, CEdG, and 8-OxodG). Plasma creatinine, eGFR, and UAE were excluded from the model as established biomarkers of diabetic nephropathy. Forward stepwise selection of variables gave a multiple logistic regression model linking diabetic nephropathy to systolic blood pressure ($B = 0.05 ± 0.02$, exponent 1.05; $P = 0.009$) and urinary excretion of CEdG ($B = 1.00 ± 0.41$, exponent 2.70; $P = 0.016$, $n = 56$). This is consistent with the increased systolic blood pressure found in patients with diabetic nephropathy and the positive correlation of urine CEdG with UAE, Tables 1 and 2.

4. Discussion

Herein we found, for the first time, increased plasma levels and urinary excretion of DNA glycation adducts in patients with T2DM and a link to diabetic nephropathy. Hence, measurement of DNA glycation adducts and nucleosides in body fluids may be valuable biomarkers of quantitative and functional important DNA damage in vivo. Glyoxal is formed in physiological systems by lipid peroxidation and degradation of glycated proteins and monosaccharides. Methylglyoxal is formed mainly by degradation of triosephosphates and also by ketone body metabolism and threonine catabolism [23]. Both dicarbonyls are metabolised by the glutathione-dependent Glo1 [6] recently linked mechanistically to the development of diabetic nephropathy [14]. Glycation of DNA by glyoxal and methylglyoxal has been linked to DNA strand breaks and mutagenesis [27, 28], and cellular dicarbonyl concentrations increase in oxidative stress [29]. Formation of MGDG and CEdG by glycation of DNA with endogenous methylglyoxal may explain the previously reported enhancement of DNA modification by glucose metabolites under conditions of glutathione depletion [30], increased DNA unwinding, and single-strand breaks of DNA in vascular endothelial cell in hyperglycemia in vitro [31] and increased single-strand breaks of DNA of patients with diabetes [32].

In previous studies we found levels of GdG and CEdG residues in peripheral lymphocyte DNA of healthy people to be similar to those of 8-OxodG, and the DNA content of MGDG exceeded that of the widely studied 8-OxodG [5]. Nucleotide AGE content of DNA was also markedly higher than that of other physiological aldehydes—such as 4-hydroxynonenal and malondialdehyde [33]. Modification of DNA by physiological dicarbonyls therefore gives rise to quantitatively important steady-state levels of deoxyguanosine-derived adducts in cellular DNA in vivo.
TABLE 2: Correlation analysis of nucleotide glycation and oxidation analytes with clinical chemical variables of renal function.

| Parameter  | Creatinine Plasma | eGFR | UAE | GdG Plasma | MGdG Plasma | CEdG Plasma | 8-OxodG Plasma | GdG Urine | MGdG Urine | CEdG Urine | 8-OxodG Urine |
|------------|-------------------|------|-----|------------|-------------|-------------|----------------|-----------|------------|------------|---------------|
| Creatinine Plasma |                   |      |     |            |              |             |                |           |            |            |               |
| eGFR       |                   | 0.38* |     |            |              |             |                |           |            |            |               |
| UAE        |                   |       | 0.42**|            |              |             |                |           |            |            |               |
| GdG Plasma |                   |       |     | 0.37***    |              |             |                |           |            |            |               |

Bivariate regression was by nonparametric, Spearman method. Significance: ** and ***; P < 0.01 and P < 0.001.
In patients with T2DM, there were particularly large increases in glyoxal-derived imidazopurine GdG in plasma and urine and 8-OxodG in urine. We cannot discriminate between the contributions to glycated and oxidised nucleosides formed by repair of glycated and oxidised DNA and formed by direct glycation and oxidation of deoxyguanosine. Formation of GdG in patients with T2DM appears to be particularly favoured. For methylglyoxal-derived metabolites, CEdG is more stable chemically than MGdG and may be a more robust biomarker when released from cells [5]. LC-MS/MS analysis of urinary excretion of CEdG in streptozotocin-induced diabetic rats indicated a 4-fold increase in CEdG excretion in diabetes with respect to normal healthy control rats [34]. Increased formation of glyoxal and methylglyoxal and oxidative stress in hyperglycemia associated with diabetes has been linked to microvascular complications—including diabetic nephropathy [1, 35]. Related damage to proteins [36] and herein DNA provides potential markers of nephropathy development.

We assessed the link of urinary excretion of nucleoside glycation and oxidation adducts as potential noninvasive biomarkers of diabetic nephropathy. In multiple logistic regression analysis, urinary CEdG emerged as a positive correlate for diabetic nephropathy. Urinary CEdG also correlated positively with UAE and hence is linked to an established biomarker of diabetic nephropathy. It also likely reflects increased exposure to methylglyoxal. CEdG has higher chemical stability than MGdG and higher biological stability than methylglyoxal in cells and physiological fluids which may explain its greater diagnostic value than these related metabolites [5, 22].

Plasma and urinary 8-OxodG were also increased in patients with T2DM. Urinary oxidation adducts of RNA rather than DNA were associated with mortality in a prospective study of patient with T2DM [37]. Increased urinary 8-OxodG in patients with T2DM was found previously but the technique used, liquid chromatography with electrochemical detection, appears to have overestimated urinary levels of 8-OxodG by ca. 10-fold [11, 12]. The greater sensitivity and specificity for analyte detection provided by multiple reaction monitoring detection in LC-MS/MS accounts for this. The two major analytical approaches that have been used for the measurement of urinary 8-OxodG prior to application of LC-MS/MS were HPLC combined with electrochemical detection and immunoassay. Approaches other than LC-MS/MS have overestimated 8-OxodG [38–40]. Estimates of urinary 8-OxodG herein are similar to independent estimates by stable isotope dilution analysis LC-MS/MS for healthy controls [41] and patients with T2DM [42]. Similar improvements have been made in the detection of CEdG by LC-MS/MS. CEdG was determined in urine of normal healthy human subjects previously by immunoassay with estimates in the range of 3.4–344 pmol/mg creatinine and median of ca. 30 pmol/mg creatinine [43]. Estimation herein by LC-MS/MS gave median (minimum–maximum) values of 0.55 (0.17–1.58) pmol/mg creatinine. Smaller studies using immunoassay procedures overestimated urinary CEdG by ca. 50-fold, as was found for similar ELISA and LC-MS/MS measurement of 8-OxodG [39]. Overestimation is likely caused by interference due to imperfect epitope specificity of the monoclonal antibody used and formation of CEdG from MGdG and other sample components during the high pH of preanalytic sample processing.

A weakness of this study was lack of females in the healthy control study group but there was no indication in the T2DM group that DNA damage marker levels were linked to gender.

5. Conclusion

From the quantitative amount and link to functional endpoints, GdG, MGdG, and CEdG adducts are of likely pathogenic and diagnostic significance. Recent further evidence linking dicarbonyl glycation with development of DN [14] suggests that DNA dicarbonyl adducts may emerge as biomarkers of development of DN. This study suggests that dicarbonyl adducts are not surrogate measures of metabolic control and some are linked to DN.

Abbreviations

A1C: Glycated haemoglobin
AGE: Advanced glycation endproduct
CEdG and CEdGa/CEDGb: deoxyguanosine and R/S epimers
dG: Deoxyguanosine
GdG: 3-(2'-Deoxyriboyl)-6,7-dihydro-6,7-dihydroxymimidazo-[2,3-b]purin-9(8)one
eGFR: Estimated glomerular filtration rate
Glo1: Glyoxalase 1
8-OxodG: 7,8-Dihydro-8-oxo-2'-deoxyguanosine
4HNE: 4-Hydroxynonenal
MGdG: 3-(2'-Deoxyriboyl)-6,7-dihydro-6,7-dihydroxymimidazo-[2,3-b]purine-9(8)one
LC-MS/MS: Liquid chromatography with tandem mass spectrometric detection
UAE: Urinary albumin excretion
DN: Diabetic nephropathy

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Sahar Waris researched the data, Brigitte M. Winklhofer-Roob, Johannes M. Roob, Sebastian Fuchs, and Harald Sourj performed subject recruitment and sample collection, Brigitte M. Winklhofer-Roob also edited the paper, and Naiia Rabbani and Paul J. Thornalley researched the data and wrote the paper.
Acknowledgments

Sahar Waris thanks the Commonwealth Scholarship Commission for a split-site Ph.D. studentship and was on secondment from Department of Biochemistry, Faculty of Medicine, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh PIN 202002, India. The project was also funded by the Commission of the European Communities, 6th Framework Programme Priority 1, Life Sciences, Genomics and Biotechnology for Health, LSHM-CT-2005-018733, PREDICTIONS (Prevention of Diabetic Complications), and 5th Framework Programme, Key Action 1, Food, Nutrition and Health, QLK1-CT-1999-00830. VITAGE (Vitamin A, Vitamin E and Carotenoid Status and Metabolism during Ageing: Functional and Nutritional Consequences). The authors thank Astrid Knopf and Sandra Wuga, Human Nutrition AND Metabolism Research and Training Center, Institute of Molecular Biosciences, Karl Franzens University of Graz, Austria, for excellent technical assistance.

References

[1] A. C. McLellan, P. J. Thornalley, J. Benn, and P. H. Sonksen, “Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications,” Clinical Science, vol. 87, no. 1, pp. 21–29, 1994.
[2] N. Rabbani and P. J. Thornalley, “Dicarboxyls (glyoxal, methylglyoxal, and 3-deoxyglucose),” in Uremic Toxins, pp. 177–192, John Wiley & Sons, 2012.
[3] J. W. Baynes, “Role of oxidative stress in development of complications in diabetes,” Diabetes, vol. 40, no. 4, pp. 405–412, 1991.
[4] P. Dandona, K. Thusu, S. Cook et al., “Oxidative damage to DNA in diabetes mellitus,” The Lancet, vol. 347, no. 8999, pp. 444–445, 1996.
[5] P. J. Thornalley, S. Waris, T. Fleming et al., “Imidazopurinones are markers of physiological genomic damage linked to DNA instability and glyoxalase 1-associated tumour multidrug resistance,” Nucleic Acids Research, vol. 38, no. 16, Article ID gko306, pp. 5432–5442, 2010.
[6] M. Xue, N. Rabbani, and P. J. Thornalley, “Glyoxalase in ageing,” Seminars in Cell and Developmental Biology, vol. 22, no. 3, pp. 293–301, 2011.
[7] A. Bierhaus, T. Fleming, S. Stoyanov et al., “Methylglyoxal modification of Na+1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy,” Nature Medicine, vol. 18, no. 6, pp. 926–933, 2012.
[8] P. Palsamy and S. Subramanian, “Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling,” Biochimica et Biophysica Acta, vol. 1812, no. 7, pp. 719–731, 2011.
[9] M. T. Barati, M. L. Merchant, A. B. Kain, A. W. Jevans, K. R. McLeish, and J. B. Klein, “Proteomic analysis defines altered cellular redox pathways and advanced glycation end-product metabolism in glomeruli of db/db diabetic mice,” American Journal of Physiology: Renal Physiology, vol. 293, no. 4, pp. F1157–F1165, 2007.
[10] N. Kachachalias, R. Babaei-Jadidi, N. Rabbani, and P. J. Thornalley, “Increased protein damage in renal glomeruli, retina, nerve, plasma and urine and its prevention by thiamine and ben Fotiamine therapy in a rat model of diabetes,” Diabetologia, vol. 53, no. 7, pp. 1506–1516, 2010.
[11] Y. Hinokio, S. Suzuki, M. Hirai, M. Chiba, A. Hirai, and T. Toyota, “Oxidative DNA damage in diabetes mellitus: its association with diabetic complications,” Diabetologia, vol. 42, no. 8, pp. 995–998, 1999.
[12] Y. Hinokio, S. Suzuki, M. Hirai, C. Suzuki, M. Suzuki, and T. Toyota, “Urinary excretion of 8-oxo-7, 8-dihydro-2′-deoxyguanosine as a predictor of the development of diabetic nephropathy,” Diabetologia, vol. 45, no. 6, pp. 877–882, 2002.
[13] W. Seidel and M. Pschetsrieder, “DNA-glycation leads to depurination by the loss of N2-carboxymethylguanine in vitro,” Cellular and Molecular Biology, vol. 44, no. 7, pp. 1165–1170, 1998.
[14] F. Giacco, X. Du, V. D. D’Agati et al., “Knockdown of glyoxalase 1 mimics diabetic nephropathy in nondiabetic mice,” Diabetes, vol. 63, no. 1, pp. 291–299, 2014.
[15] N. Rabbani and P. J. Thornalley, “The critical role of methylglyoxal and glyoxalase 1 in diabetic nephropathy,” Diabetes, vol. 63, no. 1, pp. 50–52, 2014.
[16] C. E. Vaca, J. L. Fang, M. Conradi, and S.-M. Hou, “Development of a 32P-postlabelling method for the analysis of 2′-deoxyguanosine-3′-monophosphate and DNA adducts of methylglyoxal,” Carcinogenesis, vol. 15, no. 9, pp. 1887–1894, 1994.
[17] H. Li, S. Nakamura, S. Miyazaki et al., “N2-carboxymethyl2′-deoxyguanosine, a DNA glycation marker, in kidneys and aortas of diabetic and uremic patients,” Kidney International, vol. 69, no. 2, pp. 388–392, 2006.
[18] M. S. Cooke, R. Olimski, S. Loft, and European Standards Committee on Urinary Lesion, “Measurement and meaning of oxidatively modified DNA lesions in urine,” Cancer Epidemiol Biomarkers Prevention, vol. 17, no. 1, pp. 3–14, 2008.
[19] K. Rossing, H. Mischak, M. Dakna et al., “Urinary proteinomics in diabetes and CKD,” Journal of the American Society of Nephrology, vol. 19, no. 7, pp. 1283–1290, 2008.
[20] E. Rock, B. M. Winklhofer-Roob, J. Ribalta et al., “Vitamin A, vitamin E and carotenoid status and metabolism during ageing: functional and nutritional consequences (Vitage Project),” Nutrition, Metabolism and Cardiovascular Diseases, vol. 11, no. 4, supplement, pp. 70–73, 2001.
[21] American-Diabetes-Association, “Standards of Medical Care in Diabetes—2014,” Diabetes Care, vol. 37, supplement 1, pp. S14–S80, 2013.
[22] N. Rabbani and P. J. Thornalley, “Dicarboxyl stress in cell and tissue dysfunction contributing to ageing and disease,” Biochemical and Biophysical Research Communications, vol. 458, no. 2, pp. 221–226, 2015.
[23] P. J. Thornalley, “Dicarboxyl intermediates in the Maillard reaction,” Annals of the New York Academy of Sciences, vol. 1043, pp. 111–117, 2005.
[24] F. Illadis, T. Didangelos, A. Ntemka et al., “Glucomer filtration rate estimation in patients with type 2 diabetes: creatinine- or cystatin C-based equations?” Diabetologia, vol. 54, no. 12, pp. 2987–2994, 2011.
[25] E. Urrechaga, E. Bereciartua, E. Crespo, and C. Izcara, “Evaluation of AdamsTM A1C Menarini HA–8180 HPLC analyser for HbA1c determination,” Clinical Chemistry and Laboratory Medicine, vol. 49, p. S406, 2011.
[26] M.-A. Gall, P. Hougaard, K. Borch-Johnsen, and H.-H. Parving, “Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study,” British Medical Journal, vol. 314, no. 7083, pp. 783–788, 1997.
[27] N. Murata-Kamiya, H. Kamiya, H. Kaji, and H. Kasai, “Glyoxal, a major product of DNA oxidation, induces mutations at G:C sites on a shuttle vector plasmid replicated in mammalian cells,” *Nucleic Acids Research*, vol. 25, no. 10, pp. 1897–1902, 1997.

[28] N. Murata-Kamiya, H. Kamiya, H. Kaji, and H. Kasai, “Methylglyoxal induces G:C to C:G and G:C to T:A transversions in the supF gene on a shuttle vector plasmid replicated in mammalian cells,” *Mutation Research*, vol. 468, no. 2, pp. 173–182, 2000.

[29] E. A. Abordo, H. S. Minhas, and P. J. Thormaile, “Accumulation of α,ω-oxoaldehydes during oxidative stress: a role in cytotoxicity,” *Biochemical Pharmacology*, vol. 58, no. 4, pp. 641–648, 1999.

[30] T. K. Shires, J. Tresnak, M. Kaminsky, S. L. Herzog, and B. TruPham, “DNA modification in vivo by derivatives of glucose: enhancement by glutathione depletion,” *The FASEB Journal*, vol. 4, no. 15, pp. 3340–3346, 1990.

[31] M. Lorenzi, D. F. Montisano, S. Toledo, and A. Barrieux, “High glucose induces DNA damage in cultured human endothelial cells,” *The Journal of Clinical Investigation*, vol. 77, no. 1, pp. 322–325, 1986.

[32] M. Lorenzi, D. F. Montisano, S. Toledo, and H.-C. H. Wong, “Increased single strand breaks in DNA of lymphocytes from diabetic subjects,” *Journal of Clinical Investigation*, vol. 79, no. 2, pp. 653–656, 1987.

[33] R. de Bont and N. van Larebeka, “Endogenous DNA damage in humans: a review of quantitative data,” *Mutagenesis*, vol. 19, no. 3, pp. 169–185, 2004.

[34] T. Synold, B. Xi, G.E. Wünschell et al., “Advanced glycation end products of DNA: quantification of N2-(1-carboxyethyl)-2′-deoxyguanosine in biological samples by liquid chromatography electrospray ionization tandem mass spectrometry,” *Chemical Research in Toxicology*, vol. 21, no. 11, pp. 2148–2155, 2008.

[35] M. Brownlee, “Biochemistry and molecular cell biology of diabetic complications,” *Nature*, vol. 414, no. 6865, pp. 813–820, 2001.

[36] N. Rabbani, A. Adaikalakoteswari, K. Rossing et al., “Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria,” *Amino Acids*, vol. 42, no. 5, pp. 1627–1639, 2012.

[37] K. Broedbaek, V. Siersma, T. Henriksen et al., “Association between urinary markers of nucleic acid oxidation and mortality in type 2 diabetes: a population-based cohort study,” *Diabetes Care*, vol. 36, no. 3, pp. 669–676, 2013.

[38] K. Broedbaek, A. Weimann, E. S. Stovgaard, and H. E. Poulsen, “Urinary 8-oxo-7,8-dihydro-2′-deoxyguanosine as a biomarker in type 2 diabetes,” *Free Radical Biology and Medicine*, vol. 51, no. 8, pp. 1473–1479, 2011.

[39] M. S. Cooke, R. Singh, G. K. Hall et al., “Evaluation of enzyme-linked immunosorbent assay and liquid chromatography-tandem mass spectrometry methodology for the analysis of 8-oxo-7,8-dihydro-2′-deoxyguanosine in saliva and urine,” *Free Radical Biology and Medicine*, vol. 41, no. 12, pp. 1829–1836, 2006.

[40] L. Barregard, P. Måller, T. Henriksen et al., “Human and methodological sources of variability in the measurement of urinary 8-oxo-7,8-dihydro-2′-deoxyguanosine,” *Antioxidants and Redox Signaling*, vol. 18, no. 18, pp. 2377–2391, 2013.

[41] K. Broedbaek, R. Ribel-Madsen, T. Henriksen et al., “Genetic and environmental influences on oxidative damage assessed in elderly Danish twins,” *Free Radical Biology and Medicine*, vol. 50, no. 11, pp. 1488–1491, 2011.
